HELM INTELLIGENCEPFE
Preparing your analysis.
We’re bringing the available data and research into view. Your report will appear here when it’s ready.
Working on your request
We’re bringing the available data and research into view. Your report will appear here when it’s ready.
Investors should consider both the high dividend yield and the declining growth metrics when assessing Pfizer's stock.
Pfizer Inc has a market capitalization of $161.51B and is currently trading at $28.27, reflecting a day change of +1.58%. The stock has a P/E ratio of 20.79 and an EPS growth rate of -3.55% year-over-year, while revenue has decreased by 1.65% in the same period. The current ratio stands at 1.16 and the debt-to-equity ratio is 0.71.
Some investors cite that Pfizer's dividend yield exceeds 6%, which may attract income-focused investors. Additionally, the stock is currently trading at less than 10 times earnings, suggesting potential value for those looking at long-term holdings.
Conversely, concerns have been raised about Pfizer's declining EPS growth of -3.55% and revenue growth of -1.65% year-over-year, indicating potential challenges in sustaining profitability. Analysts also question whether the stock is overvalued, despite recent oncology progress.
Hold PFE? See what it does to your whole book.
Connect a brokerage read-only and Helm shows PFE next to everything you hold: how concentrated you are, what moved today, and a daily brief on all of it. Free, no card.
See PFE in my portfolioHelm provides financial data for informational purposes only. This is not financial, investment, or tax advice. Consult a qualified professional before making financial decisions.
Watch my tickers
Get an email when something changes on your tickers: the exact quote, dated and sourced. No account, no brokerage connection, unsubscribe anytime.
Hold PFE? See what it does to your whole book.
Connect a brokerage read-only and Helm shows PFE next to everything you hold: how concentrated you are, what moved today, and a daily brief on all of it. Free, no card.
See PFE in my portfolioPfizer Inc has a market capitalization of $161.51B and is currently trading at $28.27, reflecting a day change of +1.58%. The stock has a P/E ratio of 20.79 and an EPS growth rate of -3.55% year-over-year, while revenue has decreased by 1.65% in the same period. The current ratio stands at 1.16 and the debt-to-equity ratio is 0.71.
Conversely, concerns have been raised about Pfizer's declining EPS growth of -3.55% and revenue growth of -1.65% year-over-year, indicating potential challenges in sustaining profitability. Analysts also question whether the stock is overvalued, despite recent oncology progress.
Some investors cite that Pfizer's dividend yield exceeds 6%, which may attract income-focused investors. Additionally, the stock is currently trading at less than 10 times earnings, suggesting potential value for those looking at long-term holdings.
Some investors cite that Pfizer's dividend yield exceeds 6%, which may attract income-focused investors. Additionally, the stock is currently trading at less than 10 times earnings, suggesting potential value for those looking at long-term holdings. Conversely, concerns have been raised about Pfizer's declining EPS growth of -3.55% and revenue growth of -1.65% year-over-year, indicating potential challenges in sustaining profitability. Analysts also question whether the stock is overvalued, despite recent oncology progress.
Pfizer Inc has a market capitalization of $161.51B and is currently trading at $28.27, reflecting a day change of +1.58%. The stock has a P/E ratio of 20.79 and an EPS growth rate of -3.55% year-over-year, while revenue has decreased by 1.65% in the same period. The current ratio stands at 1.16 and the debt-to-equity ratio is 0.71.
Helm's analysis is generated by an AI model from live market data. It identifies risk signals, opportunities, and key metrics based on current fundamentals, recent price action, and analyst consensus. It does not execute trades, issue certified investment advice, or predict future prices.
Not financial advice. Informational use only. AI-generated content may contain errors. Consult a licensed financial advisor before making investment decisions. Helm Terminal is not registered as an investment advisor.
Helm Terminal offers free AI-powered stock analysis for PFE at helmterminal.dev/analyze/PFE, updated continuously during US market hours. No signup required.